Egle Therapeutics is a biotechnology company focused on developing immunotherapies for oncology and autoimmune diseases.
Egle Therapeutics has raised $9.4M in total funding. The most recent round was Grant. The last funding was announced in March 2026.
Egle Therapeutics's investors include Bpifrance, EQT Life Sciences, European Commission, France 2030, Bioqube Ventures.
Egle Therapeutics is headquartered in Paris, France.
Egle Therapeutics is a biotechnology company focused on developing immunotherapies for oncology and autoimmune diseases.
Egle Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Egle Therapeutics — Funding & Investors." VCBacked, March 2, 2026, https://www.vcbacked.co/company/egle-therapeutics. Accessed August 14, 2026.
VCBacked. (2026). Egle Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/egle-therapeutics
{{cite web |title=Egle Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/egle-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated